Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression.

Maes M.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):664-75. doi: 10.1016/j.pnpbp.2010.06.014. Epub 2010 Jun 20. Review.

PMID:
20599581
2.
3.
6.

In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression.

Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):744-59. doi: 10.1016/j.pnpbp.2010.08.026. Epub 2010 Sep 7. Review.

PMID:
20828592
7.

Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development?

Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D.

Curr Med Chem. 2011;18(2):245-55. Review.

PMID:
21110802
8.

Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression.

Maes M, Ringel K, Kubera M, Berk M, Rybakowski J.

J Affect Disord. 2012 Feb;136(3):386-92. doi: 10.1016/j.jad.2011.11.016. Epub 2011 Dec 12.

PMID:
22166399
10.
12.

Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression.

Maes M, Mihaylova I, Kubera M, Ringel K.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):169-75. doi: 10.1016/j.pnpbp.2011.09.006. Epub 2011 Sep 16.

PMID:
21945535
13.

Association between increased tryptophan degradation and depression in cancer patients.

Kurz K, Schroecksnadel S, Weiss G, Fuchs D.

Curr Opin Clin Nutr Metab Care. 2011 Jan;14(1):49-56. doi: 10.1097/MCO.0b013e328340d849. Review.

PMID:
21076293
16.

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M.

Inflammopharmacology. 2012 Jun;20(3):127-50. doi: 10.1007/s10787-011-0111-7. Epub 2012 Jan 24. Review.

PMID:
22271002
17.

Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.

Raziuddin S, Sheikha A, Abu-Eshy S, al-Janadi M.

Cancer. 1994 May 1;73(9):2426-31.

18.

Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy.

Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, Ellner JJ.

Tuber Lung Dis. 1997;78(3-4):145-58. Review.

PMID:
9713647
19.

Chronic immune activation underlies morbid obesity: is IDO a key player?

Brandacher G, Hoeller E, Fuchs D, Weiss HG.

Curr Drug Metab. 2007 Apr;8(3):289-95. Review.

PMID:
17430117
20.

Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?

Maes M, Anderson G, Kubera M, Berk M.

Expert Opin Ther Targets. 2014 May;18(5):495-512. doi: 10.1517/14728222.2014.888417. Epub 2014 Feb 19. Review.

PMID:
24548241

Supplemental Content

Support Center